These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18506174)

  • 1. Risks and benefits of bisphosphonates.
    Coleman RE
    Br J Cancer; 2008 Jun; 98(11):1736-40. PubMed ID: 18506174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in oncology.
    Coleman RE; McCloskey EV
    Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
    Kohno N
    Int J Clin Oncol; 2008 Feb; 13(1):18-23. PubMed ID: 18307015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A; Jønler M; Folkmar TB; Lund L
    Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates as treatment of bone metastases.
    Holen I; Coleman RE
    Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of bisphosphonates in cancer treatment.
    Coleman R
    Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and metastatic bone disease.
    Barni S; Mandalà M; Cazzaniga M; Cabiddu M; Cremonesi M
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii91-95. PubMed ID: 16608996
    [No Abstract]   [Full Text] [Related]  

  • 15. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
    Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
    Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of bisphosphonates in cancer patients.
    Wu S; Dahut WL; Gulley JL
    Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis].
    Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.